TNFRSF17 and Waldenstrom macroglobulinemia: Our study may help pave the way toward clinical application of BCMA-targeted fourth-generation CAR-T cells and thus highlight a potential strategy for dealing with malignancies of BCMA overexpression such as Waldenstrom macroglobulinemia and glioblastoma/astrocytoma (57, 58).